Patients benefitting from immediate access to triptans

The downscheduling of triptans in 2021 led to a drop in prescription-only dispensings, but the biggest savings are seen in general patients, say experts General patients with intermittent migraine were likely to benefit most from the February 2021 downscheduling of triptans compared to concessional patients based on cost alone, according to an analysis by UniSA